Timothy S. Fenske

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Adam M. Petrich, Mitul Gandhi, Borko Jovanovic et al. · Blood · 2014 · 466 citations

Medicine, Oncology, Hematologic Oncology +9

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Nirav N. Shah, Bryon D. Johnson, Dina Schneider et al. · Nature Medicine · 2020 · 459 citations

Life Sciences, Immunology, Oncology +16

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 454 citations · Full text

Medicine, Oncology, Pharmacology +12

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors

Abraham S. Kanate, Alberto Mussetti, Mohamed A. Kharfan‐Dabaja et al. · Blood · 2015 · 271 citations · Full text

Medicine, Hematology, Immunology +15